If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> CARDIOLOGY<br /> ISSN 2053-4213 Vol 7.1 • October 2019 • europeanmedical-journal.com<br /> + Review of<br /> ESC 2019<br /> Paris, France<br /> Contents<br /> + EDITORIAL BOARD 4<br /> + CONGRESS REVIEW<br /> Review of the European Society of Cardiology (ESC) Congress 2019, 10<br /> held in Paris, France, 31st August – 4th September 2019.<br /> + CONGRESS FEATURE<br /> Digital Ripples in the Cardiovascular Pond 24<br /> Michael Dodsworth<br /> + CONGRESS INTERVIEW<br /> Prof Thomas F. Lüscher 27<br /> + SYMPOSIUM REVIEWS<br /> The Bigger Picture in Stroke Prevention and<a title="EMJ Cardiology 7.1 2019 page 1" href="http://viewer.zmags.com/publication/cd83b52f?page=1"> CARDIOLOGY ISSN 2053-4213 </a> <a title="EMJ Cardiology 7.1 2019 page 2" href="http://viewer.zmags.com/publication/cd83b52f?page=2"> Contents + EDITORIAL BOARD </a> <a title="EMJ Cardiology 7.1 2019 page 3" href="http://viewer.zmags.com/publication/cd83b52f?page=3"> “Cardiovascular diseases are the w</a> <a title="EMJ Cardiology 7.1 2019 page 4" href="http://viewer.zmags.com/publication/cd83b52f?page=4"> Editorial Board Editor-in-Chief Dr Çetin Ero</a> <a title="EMJ Cardiology 7.1 2019 page 5" href="http://viewer.zmags.com/publication/cd83b52f?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Cardiology 7.1 2019 page 6" href="http://viewer.zmags.com/publication/cd83b52f?page=6"> EMJ Cardiol. 7.1 Chief Executive Officer Spen</a> <a title="EMJ Cardiology 7.1 2019 page 7" href="http://viewer.zmags.com/publication/cd83b52f?page=7"> Welcome It is with great pleasure that I welc</a> <a title="EMJ Cardiology 7.1 2019 page 8" href="http://viewer.zmags.com/publication/cd83b52f?page=8"> MEDICATION ALONE IS NOT ENOUGH TO HELP ALL HEART </a> <a title="EMJ Cardiology 7.1 2019 page 9" href="http://viewer.zmags.com/publication/cd83b52f?page=9"> Foreword Dear colleagues, The European Society o</a> <a title="EMJ Cardiology 7.1 2019 page 10" href="http://viewer.zmags.com/publication/cd83b52f?page=10"> </a> <a title="EMJ Cardiology 7.1 2019 page 11" href="http://viewer.zmags.com/publication/cd83b52f?page=11"> Congress Review Review of the European Society </a> <a title="EMJ Cardiology 7.1 2019 page 12" href="http://viewer.zmags.com/publication/cd83b52f?page=12"> Our hand-picked selection of abstracts from ESC h</a> <a title="EMJ Cardiology 7.1 2019 page 13" href="http://viewer.zmags.com/publication/cd83b52f?page=13"> "As the digital era seemingly takes over ever</a> <a title="EMJ Cardiology 7.1 2019 page 14" href="http://viewer.zmags.com/publication/cd83b52f?page=14"> Additional Non-Culprit Lesion Intervention Offers</a> <a title="EMJ Cardiology 7.1 2019 page 15" href="http://viewer.zmags.com/publication/cd83b52f?page=15"> Microbes may Contribute to the Destabilisation of</a> <a title="EMJ Cardiology 7.1 2019 page 16" href="http://viewer.zmags.com/publication/cd83b52f?page=16"> “air pollution and environmental noise</a> <a title="EMJ Cardiology 7.1 2019 page 17" href="http://viewer.zmags.com/publication/cd83b52f?page=17"> Hospitalisations of Atrial Fibrillation Pati</a> <a title="EMJ Cardiology 7.1 2019 page 18" href="http://viewer.zmags.com/publication/cd83b52f?page=18"> Ticagrelor and Aspirin Combination Reduces</a> <a title="EMJ Cardiology 7.1 2019 page 19" href="http://viewer.zmags.com/publication/cd83b52f?page=19"> Depressive Symptoms can be Predictive of Hea</a> <a title="EMJ Cardiology 7.1 2019 page 20" href="http://viewer.zmags.com/publication/cd83b52f?page=20"> Patients with Heart Failure have a Similar Risk o</a> <a title="EMJ Cardiology 7.1 2019 page 21" href="http://viewer.zmags.com/publication/cd83b52f?page=21"> HOPE-ful Results for Patients with Hypertension </a> <a title="EMJ Cardiology 7.1 2019 page 22" href="http://viewer.zmags.com/publication/cd83b52f?page=22"> Bystander Resuscitation Increase Leads to </a> <a title="EMJ Cardiology 7.1 2019 page 23" href="http://viewer.zmags.com/publication/cd83b52f?page=23"> Antithrombotic Regimen Following Coronary Ste</a> <a title="EMJ Cardiology 7.1 2019 page 24" href="http://viewer.zmags.com/publication/cd83b52f?page=24"> Digital Ripples in the Cardiovascular Pond</a> <a title="EMJ Cardiology 7.1 2019 page 25" href="http://viewer.zmags.com/publication/cd83b52f?page=25"> often offer disappointing long-term benefits d</a> <a title="EMJ Cardiology 7.1 2019 page 26" href="http://viewer.zmags.com/publication/cd83b52f?page=26"> 26 CARDIOLOGY • October 2019 </a> <a title="EMJ Cardiology 7.1 2019 page 27" href="http://viewer.zmags.com/publication/cd83b52f?page=27"> Congress Interview Prof Thomas F. Lüscher, MD, F</a> <a title="EMJ Cardiology 7.1 2019 page 28" href="http://viewer.zmags.com/publication/cd83b52f?page=28"> Indeed, EuroIntervention is published by </a> <a title="EMJ Cardiology 7.1 2019 page 29" href="http://viewer.zmags.com/publication/cd83b52f?page=29"> "the more successful that the ESC has been, the m</a> <a title="EMJ Cardiology 7.1 2019 page 30" href="http://viewer.zmags.com/publication/cd83b52f?page=30"> The Bigger Picture in Stroke Prevention and A</a> <a title="EMJ Cardiology 7.1 2019 page 31" href="http://viewer.zmags.com/publication/cd83b52f?page=31"> comorbidities. They urged delegates to not only c</a> <a title="EMJ Cardiology 7.1 2019 page 32" href="http://viewer.zmags.com/publication/cd83b52f?page=32"> Think about the Kidneys: Why does Renal Functio</a> <a title="EMJ Cardiology 7.1 2019 page 33" href="http://viewer.zmags.com/publication/cd83b52f?page=33"> showed that AF patients treated with warfarin had</a> <a title="EMJ Cardiology 7.1 2019 page 34" href="http://viewer.zmags.com/publication/cd83b52f?page=34"> Rivaroxaban versus Phenprocoumon ESRD/dialysi</a> <a title="EMJ Cardiology 7.1 2019 page 35" href="http://viewer.zmags.com/publication/cd83b52f?page=35"> kidney disease through a variety of pathways, inc</a> <a title="EMJ Cardiology 7.1 2019 page 36" href="http://viewer.zmags.com/publication/cd83b52f?page=36"> Rate per 100 PY HR (95</a> <a title="EMJ Cardiology 7.1 2019 page 37" href="http://viewer.zmags.com/publication/cd83b52f?page=37"> References 1. The Economist Intelligence </a> <a title="EMJ Cardiology 7.1 2019 page 38" href="http://viewer.zmags.com/publication/cd83b52f?page=38"> European Society of Cardiology Chronic Coronary </a> <a title="EMJ Cardiology 7.1 2019 page 39" href="http://viewer.zmags.com/publication/cd83b52f?page=39"> of ischaemic events. This review places the new g</a> <a title="EMJ Cardiology 7.1 2019 page 40" href="http://viewer.zmags.com/publication/cd83b52f?page=40"> Recommendations for antithrombotic therapy in pat</a> <a title="EMJ Cardiology 7.1 2019 page 41" href="http://viewer.zmags.com/publication/cd83b52f?page=41"> Ischaemic events prevented and bleeding events ca</a> <a title="EMJ Cardiology 7.1 2019 page 42" href="http://viewer.zmags.com/publication/cd83b52f?page=42"> Guidelines in Perspective Professor John Eikelboo</a> <a title="EMJ Cardiology 7.1 2019 page 43" href="http://viewer.zmags.com/publication/cd83b52f?page=43"> angiotensin converting enzyme (ACE) inhibitors an</a> <a title="EMJ Cardiology 7.1 2019 page 44" href="http://viewer.zmags.com/publication/cd83b52f?page=44"> Polyvascular Disease (Coronary Artery Diseas</a> <a title="EMJ Cardiology 7.1 2019 page 45" href="http://viewer.zmags.com/publication/cd83b52f?page=45"> Conclusion Together, these case studies </a> <a title="EMJ Cardiology 7.1 2019 page 46" href="http://viewer.zmags.com/publication/cd83b52f?page=46"> Hypercholesterolaemia Management: What Will Be </a> <a title="EMJ Cardiology 7.1 2019 page 47" href="http://viewer.zmags.com/publication/cd83b52f?page=47"> statins for stable CV disease (CVD) patients and </a> <a title="EMJ Cardiology 7.1 2019 page 48" href="http://viewer.zmags.com/publication/cd83b52f?page=48"> median of 1.6 mmol/L (63 mg/dL) and achieved leve</a> <a title="EMJ Cardiology 7.1 2019 page 49" href="http://viewer.zmags.com/publication/cd83b52f?page=49"> LDL-C Reduction with statins or combo statin/ezet</a> <a title="EMJ Cardiology 7.1 2019 page 50" href="http://viewer.zmags.com/publication/cd83b52f?page=50"> Low Density Lipoprotein Cholesterol Reducing</a> <a title="EMJ Cardiology 7.1 2019 page 51" href="http://viewer.zmags.com/publication/cd83b52f?page=51"> with LDL-C has a remarkably similar effect on the</a> <a title="EMJ Cardiology 7.1 2019 page 52" href="http://viewer.zmags.com/publication/cd83b52f?page=52"> Without CHD Proportion of patients (%) Complianc</a> <a title="EMJ Cardiology 7.1 2019 page 53" href="http://viewer.zmags.com/publication/cd83b52f?page=53"> according to the 2018 American College of C</a> <a title="EMJ Cardiology 7.1 2019 page 54" href="http://viewer.zmags.com/publication/cd83b52f?page=54"> Cardiol. 2017;69(8):911-21. 12. Mega JL et al. </a> <a title="EMJ Cardiology 7.1 2019 page 55" href="http://viewer.zmags.com/publication/cd83b52f?page=55"> Interact with us on social media. </a> <a title="EMJ Cardiology 7.1 2019 page 56" href="http://viewer.zmags.com/publication/cd83b52f?page=56"> Icosapent Ethyl for the Prevention of Ca</a> <a title="EMJ Cardiology 7.1 2019 page 57" href="http://viewer.zmags.com/publication/cd83b52f?page=57"> Nordisk, PLx Pharma, Takeda; other relationships</a> <a title="EMJ Cardiology 7.1 2019 page 58" href="http://viewer.zmags.com/publication/cd83b52f?page=58"> while 27.0% had higher levels (2–10 mmol/L) that </a> <a title="EMJ Cardiology 7.1 2019 page 59" href="http://viewer.zmags.com/publication/cd83b52f?page=59"> Other genetic studies support these data, sh</a> <a title="EMJ Cardiology 7.1 2019 page 60" href="http://viewer.zmags.com/publication/cd83b52f?page=60"> among 193 patients with coronary heart disease af</a> <a title="EMJ Cardiology 7.1 2019 page 61" href="http://viewer.zmags.com/publication/cd83b52f?page=61"> 30 Patients with an event (%) HR: 0.75; 95% CI:</a> <a title="EMJ Cardiology 7.1 2019 page 62" href="http://viewer.zmags.com/publication/cd83b52f?page=62"> Prevalence of Hypertri</a> <a title="EMJ Cardiology 7.1 2019 page 63" href="http://viewer.zmags.com/publication/cd83b52f?page=63"> Eicosapentaenoic Acid Therapy is Associated wit</a> <a title="EMJ Cardiology 7.1 2019 page 64" href="http://viewer.zmags.com/publication/cd83b52f?page=64"> 5. Varbo A et al. Remnant cholesterol </a> <a title="EMJ Cardiology 7.1 2019 page 65" href="http://viewer.zmags.com/publication/cd83b52f?page=65"> 42. Zhao Y et al. Eicosapentaenoic acid </a> <a title="EMJ Cardiology 7.1 2019 page 66" href="http://viewer.zmags.com/publication/cd83b52f?page=66"> Why the Diagnosis of ATTR-Cardiomyopathy </a> <a title="EMJ Cardiology 7.1 2019 page 67" href="http://viewer.zmags.com/publication/cd83b52f?page=67"> hypertrophy, arrhythmias, ventricular blocks, rig</a> <a title="EMJ Cardiology 7.1 2019 page 68" href="http://viewer.zmags.com/publication/cd83b52f?page=68"> Almost all patients had either a cardiac (59.8%) </a> <a title="EMJ Cardiology 7.1 2019 page 69" href="http://viewer.zmags.com/publication/cd83b52f?page=69"> Cut-off values of LVAR >0.96 and RVAR >0.80 showe</a> <a title="EMJ Cardiology 7.1 2019 page 70" href="http://viewer.zmags.com/publication/cd83b52f?page=70"> Table 1: Elevated hepatocyte growth factor and N-</a> <a title="EMJ Cardiology 7.1 2019 page 71" href="http://viewer.zmags.com/publication/cd83b52f?page=71"> observational study of 251 patients wit</a> <a title="EMJ Cardiology 7.1 2019 page 72" href="http://viewer.zmags.com/publication/cd83b52f?page=72"> The Effect of De-escalated Switching </a> <a title="EMJ Cardiology 7.1 2019 page 73" href="http://viewer.zmags.com/publication/cd83b52f?page=73"> ratio [aHR] 2.18; 95% confidence interval [CI]: 1.</a> <a title="EMJ Cardiology 7.1 2019 page 74" href="http://viewer.zmags.com/publication/cd83b52f?page=74"> Th17 Signature, Autoimmunity, and Differe</a> <a title="EMJ Cardiology 7.1 2019 page 75" href="http://viewer.zmags.com/publication/cd83b52f?page=75"> Th17 cell IL-23 IL-23R C</a> <a title="EMJ Cardiology 7.1 2019 page 76" href="http://viewer.zmags.com/publication/cd83b52f?page=76"> autoimmune myocarditis. J Immunol. 2006;177(11):</a> <a title="EMJ Cardiology 7.1 2019 page 77" href="http://viewer.zmags.com/publication/cd83b52f?page=77"> as downregulation of genes associated to cell pro</a> <a title="EMJ Cardiology 7.1 2019 page 78" href="http://viewer.zmags.com/publication/cd83b52f?page=78"> Keywords: Acute coronary syndrome (ACS), cardiac </a> <a title="EMJ Cardiology 7.1 2019 page 79" href="http://viewer.zmags.com/publication/cd83b52f?page=79"> Analysing the Regulation of a Catecholamine- </a> <a title="EMJ Cardiology 7.1 2019 page 80" href="http://viewer.zmags.com/publication/cd83b52f?page=80"> might be altered in TTS, a SERCA microdomain targ</a> <a title="EMJ Cardiology 7.1 2019 page 81" href="http://viewer.zmags.com/publication/cd83b52f?page=81"> RESULTS In 1,160 patients with TF-TAVR, a broad </a> <a title="EMJ Cardiology 7.1 2019 page 82" href="http://viewer.zmags.com/publication/cd83b52f?page=82"> Summary of Artificial Intelligence in</a> <a title="EMJ Cardiology 7.1 2019 page 83" href="http://viewer.zmags.com/publication/cd83b52f?page=83"> References 1. Zhang J et al. Fully automated</a> <a title="EMJ Cardiology 7.1 2019 page 84" href="http://viewer.zmags.com/publication/cd83b52f?page=84"> Cardiac Rehabilitation in Heart Failure: </a> <a title="EMJ Cardiology 7.1 2019 page 85" href="http://viewer.zmags.com/publication/cd83b52f?page=85"> Importantly, and especially for HF with a p</a> <a title="EMJ Cardiology 7.1 2019 page 86" href="http://viewer.zmags.com/publication/cd83b52f?page=86"> New data aiming to ascertain the role of CR progr</a> <a title="EMJ Cardiology 7.1 2019 page 87" href="http://viewer.zmags.com/publication/cd83b52f?page=87"> 21. Ellingsen Ø et al. High-intensity </a> <a title="EMJ Cardiology 7.1 2019 page 88" href="http://viewer.zmags.com/publication/cd83b52f?page=88"> Want a daily dose of healthcare straight to your </a> <a title="EMJ Cardiology 7.1 2019 page 89" href="http://viewer.zmags.com/publication/cd83b52f?page=89"> Lipoprotein(a) and Calcific Aortic Valve Stenosis </a> <a title="EMJ Cardiology 7.1 2019 page 90" href="http://viewer.zmags.com/publication/cd83b52f?page=90"> INTRODUCTION Lipoprotein(a) [Lp(a)] is a complex </a> <a title="EMJ Cardiology 7.1 2019 page 91" href="http://viewer.zmags.com/publication/cd83b52f?page=91"> a strong synergism was also observed between Lp(a</a> <a title="EMJ Cardiology 7.1 2019 page 92" href="http://viewer.zmags.com/publication/cd83b52f?page=92"> compared to levels of Lp(a) <5 mg/dL.15 Notably, </a> <a title="EMJ Cardiology 7.1 2019 page 93" href="http://viewer.zmags.com/publication/cd83b52f?page=93"> it was suggested that the concept that the</a> <a title="EMJ Cardiology 7.1 2019 page 94" href="http://viewer.zmags.com/publication/cd83b52f?page=94"> thus leading to fibrin deposition on the aortic le</a> <a title="EMJ Cardiology 7.1 2019 page 95" href="http://viewer.zmags.com/publication/cd83b52f?page=95"> Moreover, it was shown that the Lp(a)</a> <a title="EMJ Cardiology 7.1 2019 page 96" href="http://viewer.zmags.com/publication/cd83b52f?page=96"> 2016;4:78-87. 13. Sofi F et al. Lipoprotein (a) </a> <a title="EMJ Cardiology 7.1 2019 page 97" href="http://viewer.zmags.com/publication/cd83b52f?page=97"> inflammation and mineralization </a> <a title="EMJ Cardiology 7.1 2019 page 98" href="http://viewer.zmags.com/publication/cd83b52f?page=98"> Management of Atrial Fibrillation in Europe:</a> <a title="EMJ Cardiology 7.1 2019 page 99" href="http://viewer.zmags.com/publication/cd83b52f?page=99"> MANAGEMENT OVERVIEW OF ATRIAL FIBRILLATION Atria</a> <a title="EMJ Cardiology 7.1 2019 page 100" href="http://viewer.zmags.com/publication/cd83b52f?page=100"> Figure 1: Current care pathways for the managemen</a> <a title="EMJ Cardiology 7.1 2019 page 101" href="http://viewer.zmags.com/publication/cd83b52f?page=101"> 5 Rhythm control therapy to maintain normal sinus</a> <a title="EMJ Cardiology 7.1 2019 page 102" href="http://viewer.zmags.com/publication/cd83b52f?page=102"> Initial Atrial Fibrillation Patient Care Pathway </a> <a title="EMJ Cardiology 7.1 2019 page 103" href="http://viewer.zmags.com/publication/cd83b52f?page=103"> recommended for use in select patient p</a> <a title="EMJ Cardiology 7.1 2019 page 104" href="http://viewer.zmags.com/publication/cd83b52f?page=104"> Table 1: Potential treatment costs for managing p</a> <a title="EMJ Cardiology 7.1 2019 page 105" href="http://viewer.zmags.com/publication/cd83b52f?page=105"> but manageable complications may occur in 2–</a> <a title="EMJ Cardiology 7.1 2019 page 106" href="http://viewer.zmags.com/publication/cd83b52f?page=106"> report a similar frequency of AE when treating pa</a> <a title="EMJ Cardiology 7.1 2019 page 107" href="http://viewer.zmags.com/publication/cd83b52f?page=107"> FUTURE DIRECTIONS The 2016 ESC/EACTS guidelines a</a> <a title="EMJ Cardiology 7.1 2019 page 108" href="http://viewer.zmags.com/publication/cd83b52f?page=108"> JAMA. 2015;314(18):1911-2. 13. Freedman B et al</a> <a title="EMJ Cardiology 7.1 2019 page 109" href="http://viewer.zmags.com/publication/cd83b52f?page=109"> to assess catheter ablation versus rate control i</a> <a title="EMJ Cardiology 7.1 2019 page 110" href="http://viewer.zmags.com/publication/cd83b52f?page=110"> A Review of the Burden of Atrial Fibrillation: </a> <a title="EMJ Cardiology 7.1 2019 page 111" href="http://viewer.zmags.com/publication/cd83b52f?page=111"> INTRODUCTION Atrial fibrillation (AF), the most co</a> <a title="EMJ Cardiology 7.1 2019 page 112" href="http://viewer.zmags.com/publication/cd83b52f?page=112"> year with AF in Europe is >886,000, but incidence</a> <a title="EMJ Cardiology 7.1 2019 page 113" href="http://viewer.zmags.com/publication/cd83b52f?page=113"> With the growing number of patients affected by A</a> <a title="EMJ Cardiology 7.1 2019 page 114" href="http://viewer.zmags.com/publication/cd83b52f?page=114"> QoL than those with chronic AF (persistent and pe</a> <a title="EMJ Cardiology 7.1 2019 page 115" href="http://viewer.zmags.com/publication/cd83b52f?page=115"> France11 (2012) Germany10,44 (2004) Ita</a> <a title="EMJ Cardiology 7.1 2019 page 116" href="http://viewer.zmags.com/publication/cd83b52f?page=116"> (€9 billion).61 The annual per-patient costs for </a> <a title="EMJ Cardiology 7.1 2019 page 117" href="http://viewer.zmags.com/publication/cd83b52f?page=117"> CONCLUSIONS This review promotes a greater awaren</a> <a title="EMJ Cardiology 7.1 2019 page 118" href="http://viewer.zmags.com/publication/cd83b52f?page=118"> Economic and Social Affairs Population Division. </a> <a title="EMJ Cardiology 7.1 2019 page 119" href="http://viewer.zmags.com/publication/cd83b52f?page=119"> Tricuspid Regurgitation: No Longer </a> <a title="EMJ Cardiology 7.1 2019 page 120" href="http://viewer.zmags.com/publication/cd83b52f?page=120"> of choice for a degenerated bio-prosthesis or det</a> <a title="EMJ Cardiology 7.1 2019 page 121" href="http://viewer.zmags.com/publication/cd83b52f?page=121"> A B C D E F G H Figure 2: Devices for per</a> <a title="EMJ Cardiology 7.1 2019 page 122" href="http://viewer.zmags.com/publication/cd83b52f?page=122"> The catheter-based system provides a </a> <a title="EMJ Cardiology 7.1 2019 page 123" href="http://viewer.zmags.com/publication/cd83b52f?page=123"> TR treatment.22 Preliminary evidence suggests tha</a> <a title="EMJ Cardiology 7.1 2019 page 124" href="http://viewer.zmags.com/publication/cd83b52f?page=124"> pitfalls that still have to be addressed, such as</a> <a title="EMJ Cardiology 7.1 2019 page 125" href="http://viewer.zmags.com/publication/cd83b52f?page=125"> improvements in quality of life and symptoms (Tab</a> <a title="EMJ Cardiology 7.1 2019 page 126" href="http://viewer.zmags.com/publication/cd83b52f?page=126"> Table 1: Summary of transcatheter tricuspid valve</a> <a title="EMJ Cardiology 7.1 2019 page 127" href="http://viewer.zmags.com/publication/cd83b52f?page=127"> References 1. Vassileva CM et al. Tricuspid </a> <a title="EMJ Cardiology 7.1 2019 page 128" href="http://viewer.zmags.com/publication/cd83b52f?page=128"> Chemokines: A Potential Therapeutic Target for th</a> <a title="EMJ Cardiology 7.1 2019 page 129" href="http://viewer.zmags.com/publication/cd83b52f?page=129"> CHEMOKINES Chemokines are a class of cytokines c</a> <a title="EMJ Cardiology 7.1 2019 page 130" href="http://viewer.zmags.com/publication/cd83b52f?page=130"> Table 1: Role of chemokines in modulating plaque </a> <a title="EMJ Cardiology 7.1 2019 page 131" href="http://viewer.zmags.com/publication/cd83b52f?page=131"> Table 1 continued. Ligand Receptor Effect</a> <a title="EMJ Cardiology 7.1 2019 page 132" href="http://viewer.zmags.com/publication/cd83b52f?page=132"> CCL2, CCL5 & CX3CL1 Pl</a> <a title="EMJ Cardiology 7.1 2019 page 133" href="http://viewer.zmags.com/publication/cd83b52f?page=133"> phenotype with increased SMC content. These findin</a> <a title="EMJ Cardiology 7.1 2019 page 134" href="http://viewer.zmags.com/publication/cd83b52f?page=134"> Neointimal recruitment of SMC is facilitated by C</a> <a title="EMJ Cardiology 7.1 2019 page 135" href="http://viewer.zmags.com/publication/cd83b52f?page=135"> However, immunotherapies have a common pitfal</a> <a title="EMJ Cardiology 7.1 2019 page 136" href="http://viewer.zmags.com/publication/cd83b52f?page=136"> with Met-RANTES show reduced macrophage and lymph</a> <a title="EMJ Cardiology 7.1 2019 page 137" href="http://viewer.zmags.com/publication/cd83b52f?page=137"> References 1. Stefanadis C et al. Coronary </a> <a title="EMJ Cardiology 7.1 2019 page 138" href="http://viewer.zmags.com/publication/cd83b52f?page=138"> plaques. Trends Cardiovasc Med. 2007;17(8):253-8.</a> <a title="EMJ Cardiology 7.1 2019 page 139" href="http://viewer.zmags.com/publication/cd83b52f?page=139"> Circulating Cardiac Biomarkers in Heart Failure: </a> <a title="EMJ Cardiology 7.1 2019 page 140" href="http://viewer.zmags.com/publication/cd83b52f?page=140"> countries, regardless of disease phenotype, has f</a> <a title="EMJ Cardiology 7.1 2019 page 141" href="http://viewer.zmags.com/publication/cd83b52f?page=141"> Table 1: Conventional and novel biological marker</a> <a title="EMJ Cardiology 7.1 2019 page 142" href="http://viewer.zmags.com/publication/cd83b52f?page=142"> potential value as an index of emerging clinical </a> <a title="EMJ Cardiology 7.1 2019 page 143" href="http://viewer.zmags.com/publication/cd83b52f?page=143"> Table 2: Accordance between serum levels of cardi</a> <a title="EMJ Cardiology 7.1 2019 page 144" href="http://viewer.zmags.com/publication/cd83b52f?page=144"> In the EPHESUS trial, HFrEF patients with i</a> <a title="EMJ Cardiology 7.1 2019 page 145" href="http://viewer.zmags.com/publication/cd83b52f?page=145"> Angiotensin Receptor-Neprilysin Inhibitors A new</a> <a title="EMJ Cardiology 7.1 2019 page 146" href="http://viewer.zmags.com/publication/cd83b52f?page=146"> References 1. Owan TE et al. Trends in preva</a> <a title="EMJ Cardiology 7.1 2019 page 147" href="http://viewer.zmags.com/publication/cd83b52f?page=147"> neurohormonal profile of spironolactone in severe </a> <a title="EMJ Cardiology 7.1 2019 page 148" href="http://viewer.zmags.com/publication/cd83b52f?page=148"> 148 CARDIOLOGY • October 2019 </a>